Pediatric Blood Pressure: AAP 2017 Guidelines, Percentiles, and Hypertension Staging

Summary

• Childhood hypertension prevalence is 2% to 5%; elevated BP affects 13% to 18% of children [1].
• A 2025 meta-analysis of 271 studies (>3.6 million children) found sustained hypertension (confirmed on ≥3 visits) in 3.89% and occasional (single-visit) hypertension in 11.85% [2].
• Diagnosis requires BP ≥95th percentile on 3 separate visits; ambulatory blood pressure monitoring (ABPM) is used to confirm the diagnosis before starting medication [3].
• Up to half of children with elevated office BP have white coat hypertension, and 9.22% have masked hypertension [6].
• Secondary hypertension prevalence is 9.0% in primary care and 44% in subspecialty clinics [8].
• ACE inhibitors and ARBs are the preferred first-line pharmacologic agents based on network meta-analysis evidence [10].

Open the AAP BP Full Calculator →

Epidemiology

Pediatric hypertension is underrecognized and carries implications for lifelong cardiovascular health [1]. Overall prevalence in childhood is 2% to 5%, with 13% to 18% of children showing elevated BP on population screening [1].

A 2025 systematic review and meta-analysis of 271 studies involving over 3.6 million children found a global prevalence of 3.89% for sustained hypertension (confirmed on ≥3 occasions) and 11.85% for occasional hypertension (single-visit diagnosis) [2].

Caution. Single-visit BP measurement overestimates true hypertension prevalence roughly 3-fold compared with 3-visit confirmation [2]. A single elevated reading is not a diagnosis.

2017 AAP Guideline: Key Changes

The AAP 2017 Clinical Practice Guideline for screening and management of high BP in children and adolescents revised the 2004 Fourth Report as follows [3]:

• Replaced "prehypertension" with "elevated blood pressure"
• Introduced new normative BP tables based on normal-weight children only, excluding overweight/obese children from the reference data
• Simplified the screening table used to identify BPs needing further evaluation
• Simplified BP classification in adolescents ≥13 years to align with adult thresholds
• Limited routine screening BP measurement to preventive care visits
• Expanded the role of ABPM in diagnosis and management
• Revised echocardiography recommendations to generally precede medication initiation only

Classification and Staging

Children aged 1 to <13 years

Children aged ≥13 years

Reference [3].

Open the AAP BP Full Calculator →

Screening

Children should have BP measured annually beginning at age 3 years at well-child visits [3]. Children younger than 3 years should have BP measured only with risk factors present: history of prematurity, very low birth weight, congenital heart disease, recurrent urinary tract infections, renal disease, solid organ transplant, malignancy, or medications known to raise BP [3][5].

Measurement Technique

• Use an appropriately sized cuff: bladder length 80% to 100% of arm circumference, width at least 40% of arm circumference [3].
• Repeat an abnormal initial reading by auscultation within the same visit if possible [3].
• Obtain up to 3 BP measurements and record the average of the latter 2 unless the first measurement is normal [3].

Diagnosis Confirmation

Hypertension is defined as average clinic-measured SBP and/or DBP ≥95th percentile on 3 separate visits [3]. For Stage 1 hypertension that persists after 3 visits, order ABPM (if available), complete diagnostic evaluation, and initiate treatment [3].

Ambulatory Blood Pressure Monitoring

ABPM is recommended to confirm the diagnosis before starting antihypertensive medication [3]. ABPM is more accurate for diagnosis than clinic BP, more predictive of future BP, and assists in detecting secondary hypertension [3]. Increased left ventricular mass index and left ventricular hypertrophy correlate more strongly with ABPM parameters than with casual clinic BP [3].

Height-Adjusted Interpretation

BP is interpreted by sex, age, and height to avoid misclassifying children who are extremely tall or extremely short [3]. Normative data were collected using an auscultatory technique, which may differ from values obtained with oscillometric devices or ABPM [3].

Clinical pearl. Two children of the same age with identical BP readings can fall into different categories depending on height percentile. Always confirm the height percentile before classifying BP in a child under 13 years.

Open the AAP BP Full Calculator →

White Coat Hypertension

White coat hypertension (WCH) is BP ≥95th percentile in the office but <95th percentile outside the clinical setting [3]. Up to half of children evaluated for elevated office BP have WCH [3]. A 2026 meta-analysis found a pooled WCH prevalence of 5.17% (95% CI 3.23-7.52), higher in low- and middle-income countries (8.13%) than high-income countries (3.70%) [6].

WCH is diagnosed by ABPM when mean SBP and DBP are <95th percentile and BP load is <25% [3]. WCH carries only slightly increased risk of adverse outcomes compared with normotension, though abnormal BP response to exercise and increased left ventricular mass have been observed in affected children [3]. Children with WCH should have BP screened at regular well-child visits, with repeat ABPM considered in 1 to 2 years [3].

Masked Hypertension

Masked hypertension, defined as normal office BP with elevated ambulatory BP, was present in 9.22% (95% CI 6.90-11.83) of children and adolescents in a 2026 meta-analysis [6]. This condition warrants additional monitoring, particularly when other risk factors are present.

Secondary Hypertension

Consider secondary hypertension in:

• Younger children, particularly under 6 years
• Stage 2 or resistant hypertension
• Symptomatic hypertension
• Acute, severe, or malignant hypertension with target organ injury

A 2023 JAMA systematic review found secondary hypertension prevalence of 9.0% (95% CI 4.5-15.0%) in primary care and 44% (95% CI 36-53%) in subspecialty clinics [8].

Findings associated with secondary hypertension

Reference [8].

Findings associated with decreased likelihood of secondary hypertension

Reference [8].

Initial Evaluation

The AAP recommends the following initial workup for confirmed hypertension [3]:

• Urinalysis, serum electrolytes, BUN, serum creatinine, lipid panel
• Renal ultrasound
• Hemoglobin A1c, liver enzymes, fasting lipid panel

Additional testing (fasting glucose, TSH, drug screening, sleep study, plasma renin/aldosterone, catecholamines, renovascular imaging) is added based on clinical suspicion [3].

Management

Lifestyle Modification

Lifestyle changes apply to all youth with high BP regardless of underlying diagnosis [3][4]:

• Dietary modification (DASH-style diet, sodium restriction)
• Increased physical activity
• Weight management if overweight or obese [4]

A 6-month trial of non-pharmacologic management typically precedes antihypertensive medication in most cases [3].

Indications for Pharmacologic Treatment

Start antihypertensive medication when a child [3]:

• Remains hypertensive despite a trial of lifestyle modification
• Has symptomatic hypertension (headaches, cognitive changes)
• Has Stage 2 hypertension without a clearly modifiable factor (e.g., obesity)
• Has any stage of hypertension with CKD or diabetes mellitus
• Has left ventricular hypertrophy on echocardiography

Obtain an echocardiogram to assess cardiac mass before starting antihypertensive medication [3].

Clinical pearl. A 6-month lifestyle trial is the default before medication. This does not apply to symptomatic hypertension, Stage 2 hypertension without a modifiable cause, or hypertension with CKD/diabetes, where pharmacologic treatment starts without waiting [3].

Choice of Agent

First-line pharmacologic options [3][10]:

• ACE inhibitor (e.g., lisinopril, enalapril)
• ARB (e.g., losartan)
• Long-acting calcium channel blocker
• Thiazide diuretic

A network meta-analysis showed ACE inhibitors and ARBs are superior to placebo for BP reduction in children, with lisinopril and enalapril showing the strongest evidence [10]. Beta-blockers are not recommended as initial treatment given their adverse effect profile and lack of outcome benefit over other agents [10].

Caution. ACE inhibitors and ARBs are contraindicated in pregnancy. Counsel adolescents of childbearing potential before prescribing [3].

Additional considerations

• African American children may show a less robust response to ACE inhibitors; consider a higher initial dose or an alternative agent [3].
• For children with CKD, proteinuria, or diabetes, an ACE inhibitor or ARB is recommended as initial therapy [3].

Treatment Targets

• <90th percentile for age, sex, and height in children <13 years [3]
• <130/80 mm Hg in children ≥13 years [3]
• More stringent targets for secondary hypertension or high-risk conditions such as CKD [3]

Long-Term Implications

Hypertensive children are highly likely to become hypertensive adults and to show measurable target organ injury, particularly left ventricular hypertrophy and vascular stiffening [7]. BP tracking data from childhood to adulthood show that higher childhood BP correlates with higher adult BP and earlier onset of hypertension in young adulthood [7].

Primary hypertension is now the most common cause of pediatric hypertension, particularly in children with obesity [1][4]. Accurate diagnosis depends on measurement rigor, confirmation across multiple visits, and height-adjusted interpretation [3].

References

1. Falkner B, Gidding SS, Baker-Smith CM, et al. Pediatric Primary Hypertension: An Underrecognized Condition: A Scientific Statement From the American Heart Association. Hypertension. 2023;80(6):e101-e111.
2. Ruan X, Zhu A, Wang T, et al. Global Prevalence of Hypertension in Children and Adolescents Younger Than 19 Years. JAMA Pediatr. 2025;179(9):987-999.
3. Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017;140(3):e20171904.
4. Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics. 2023;151(2):e2022060640.
5. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for High Blood Pressure in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;324(18):1878-1883.
6. Zhou J, Shan S, Wu J, et al. Global Prevalence of Hypertension Among Children and Adolescents Aged 19 Years or Younger: An Updated Systematic Review and Meta-Analysis. Lancet Child Adolesc Health. 2026;10(1):11-21.
7. Chanchlani R, Brady T, Kruger R, Sinha MD. Under Pressure: The Lifelong Cardiovascular Health of Children and Youth With Primary Hypertension. Lancet Child Adolesc Health. 2025;S2352-4642(25)00302-5.
8. Nugent JT, Jiang K, Funaro MC, et al. Does This Child With High Blood Pressure Have Secondary Hypertension? The Rational Clinical Examination Systematic Review. JAMA. 2023;329(12):1012-1021.
9. Riley M, Hernandez AK, Kuznia AL. High Blood Pressure in Children and Adolescents. Am Fam Physician. 2018;98(8):486-494.
10. Burrello J, Erhardt EM, Saint-Hilary G, et al. Pharmacological Treatment of Arterial Hypertension in Children and Adolescents: A Network Meta-Analysis. Hypertension. 2018;72(2):306-313.